2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106171
    NBI-6024 239480-61-6 98%
    NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients.
    NBI-6024
  • HY-106256
    HMR-3339 214140-47-3 98%
    HMR-3339 is a new selective estrogen receptor modulator. HMR-3339 reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine. HMR-3339 corrects bone alterations induced by ovariectomy.
    HMR-3339
  • HY-106297
    Tosagestin 110072-15-6 98%
    Tosagestin(Org 30659) is a 19-nortestosterone–derived progestagen. Tosagestinsuppresses ovarian function to a level sufficient to inhibit ovulation. Tosagestininhibits cell growth in T47D-S cells.
    Tosagestin
  • HY-106300
    AA 193 107804-48-8 98%
    AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia.
    AA 193
  • HY-106323
    [Leu13]-Motilin 59530-69-7 98%
    [Leu13]-Motilin (KW-5139) is a motilin analogue. [Leu13]-Motilin stimulates gastrointestinal motility in the rabbit. [Leu13]-Motilin causes concentration-dependent contractions of the gastric antrum, duodenum, jejunum, ileum and the descending colon in vitro.
    [Leu13]-Motilin
  • HY-106327
    EM-523 110205-60-2 98%
    EM-523 is a motilin agonist and an erythromycin derivative. EM-523 has pED50 values of 8.19 and 6.08 for promoting contractions in rabbit small intestinal tissue and human duodenal tissue, respectively. EM-523 can be used in the research of gastrointestinal diseases.
    EM-523
  • HY-106380
    Glenvastatin 122254-45-9 98%
    Glenvastatin (HR 780) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Glenvastatin can reduces plasma total cholesterol and phospholipid levels and liver cholesterol contents. Glenvastatin does not increase the contents of cholesterol and total bile acid in the gallbladder bile. Glenvastatin can be used for the research of hyperlipemia
    Glenvastatin
  • HY-106417
    Limazocic 128620-82-6 98%
    Limazocic (SA 3443) is an orally active hepatoprotective agent. Limazocic can inhibit increases in serum transaminase, alkaline phosphatase activity and hepatic lipids, hydroxyproline content induced by CCl4. Limazocic can decrease the degree of hepatic necrosis, fibrosis and steatosis. Limazocic can be used for the research of chronic liver injuries.
    Limazocic
  • HY-106518
    Adimolol free base 78459-19-5
    Adimolol (free base) (MEN 935 (free base)) is an antagonist of β- and α-adrenolytic receptor. Adimolol (free base) shows Kis of 5.2 x 10-7, 1.3 x 10-5 mol/L at α1 and α2 drenoceptors, respectively. Adimolol (free base) can be used for antihypertensive study.
    Adimolol free base
  • HY-106537
    W 3699 17243-64-0 98%
    W 3699 (Probilin; Secrebil; Piprozolin) is a choleretic agent that can be used in the study of biliary diseases.
    W 3699
  • HY-106580
    Plafibride 63394-05-8 98%
    Plafibride (ITA 104) is an orally active hypolipemic, platelet aggregation inhibitor.
    Plafibride
  • HY-106581
    Pirifibrate 55285-45-5 98%
    Pirifibrate (EL-466) is a lipid-lowering compound. Pirifibrate slightly increases α-lipoprotein levels. Pirifibrate can be used for the research of type IIa, IIb and IV hyperlipoproteinemia.
    Pirifibrate
  • HY-106604
    Lortalamine 70384-91-7 98%
    Lortalamine (LM 1404) is a selective norepinephrine transporter inhibitor with an IC50 of <1 nM. Lortalamine is a non-tricyclic antidepressant. Lortalamine antagonises Reserpine (HY-N0480)-induced ptosis and hypothermia. Lortalamine inhibits norepinephrine uptake.
    Lortalamine
  • HY-106619
    Seprilose 133692-55-4 98%
    Seprilose (GW 80126) is a prostaglandin E2 inhibitor that can inhibit prostaglandin E2 synthesis.
    Seprilose
  • HY-106661
    GLY-230 320777-05-7 98%
    GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction.
    GLY-230
  • HY-106744
    Azetirelin 95729-65-0 98%
    Azetirelin (YM-14673) is an analogue of thyrotropin-releasing hormone (TRH).
    Azetirelin
  • HY-106767
    Dulofibrate 61887-16-9 98%
    Dulofibrate is a hypolipidaemic agent that induces microsomal drug-metabolizing enzymes. Dulofibrate is selective for a reduction in triglycerides. Dulofibrate decreases nopol conjugation.
    Dulofibrate
  • HY-106827
    Trimegestone 74513-62-5 98%
    Trimegestone (RU 27987) is an orally active, selective progestogen and PR ligand, with an IC50 of 7.6 nM for hPR, 4.4 nM for rabbit PR, and 3.3 nM for rat PR. Trimegestone induces Alkaline phosphatase activity. Trimegestone exhibits antiandrogenic activity (IC50 = 303 nM). Trimegestone can be used in research related to menopausal symptoms and osteoporosis.
    Trimegestone
  • HY-106828
    E2-CDS 103562-82-9 98%
    E2-CDS (Estradiol 17-Dihydrotrigonelline) is a redox-based chemical delivery system for estradiol (E2). E2-CDS is capable of sustained and brain-selective delivery of estradiol.
    E2-CDS
  • HY-106839
    NKS-01 120051-39-0 98%
    NKS-01 is a selective estrogen receptor modulator. NKS-01 can be used for the research of cancer, such as estrogen receptor-positive breast cancer.
    NKS-01
Cat. No. Product Name / Synonyms Application Reactivity